FDA Approves First Myopia Treatment for Children and Barth Syndrome Therapy in September 2025

September 2025 delivered several groundbreaking regulatory approvals that address critical unmet medical needs in pediatric populations and rare diseases. The month was marked by notable firsts in FDA authorizations, alongside important safety updates for commonly used medications.

First Myopia Treatment Approved for Children

On September 25, the FDA authorized the marketing of Essilor Stellest (搜索)搜索该药品 eyeglass lenses, representing the first approved treatment specifically designed to slow the progression of myopia (搜索)搜索该疾病 in children aged 6 to 12. This approval addresses a growing public health concern, as myopia affects approximately 40% of the U.S. population, with rates rising rapidly among children and adolescents.

The authorization of Stellest lenses fills a significant gap in pediatric eye care, providing healthcare providers with the first FDA-approved option to actively manage myopia (搜索)搜索该疾病 progression rather than simply correcting vision. The chronic nature of myopia and its increasing prevalence in younger populations makes this approval particularly significant for long-term eye health outcomes.

Breakthrough Treatment for Rare Mitochondrial Disorder

Just days earlier, on September 19, the FDA granted accelerated approval to Stealth Biotherapeutics (搜索)搜索该词条' Forzinity (搜索)搜索该药品, marking a historic milestone as the first-ever treatment for Barth syndrome (搜索)搜索该疾病. This life-threatening mitochondrial disorder previously had no approved therapeutic options, leaving patients and families with extremely limited treatment alternatives.

The accelerated approval pathway reflects the urgent medical need for Barth syndrome (搜索)搜索该疾病 treatments and the drug's potential to address a condition with no existing therapeutic options. Forzinity (搜索)搜索该药品's approval represents a significant advancement in the treatment of rare mitochondrial disorders and provides hope for patients affected by this devastating condition.

Safety Updates for Common Pain Medication

The regulatory landscape in September also included important safety considerations for widely used medications. On September 22, the FDA initiated the process of updating labeling for acetaminophen查看药品详情 (Tylenol) to warn of potential associations between use during pregnancy and increased risk of autism (搜索)搜索该疾病 and ADHD (搜索)搜索该疾病 in children.

This labeling update affects one of the most commonly used analgesics and reflects the FDA's ongoing commitment to ensuring medication safety information remains current with emerging scientific evidence. The potential impact on pregnant women and their healthcare providers could be substantial, given acetaminophen查看药品详情's widespread use during pregnancy.

Regulatory Context and Broader Implications

These September approvals come as the FDA continues its steady pace of novel drug approvals in 2025. Through August, the agency had approved 26 novel drugs, slightly trailing the 29 approvals recorded during the same period in the previous year. The month's approvals demonstrate the FDA's continued focus on addressing unmet medical needs, particularly in pediatric populations and rare diseases.

The timing of these approvals during September, which coincides with World Alzheimer's Month, Blood Cancer Awareness Month, and Childhood Cancer Awareness Month, underscores the ongoing efforts to advance treatments across multiple therapeutic areas. The pediatric focus of both the myopia (搜索)搜索该疾病 treatment and the safety updates for acetaminophen查看药品详情 highlights the agency's attention to children's health needs.